The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Olav Hellebo was appointed to CEO in Sep 2014 he was listed as having 322,778 shares in Jan 2015 , He is now listed as having only 50,201 shares so must have sold down to this figure which now equates to 0.09% of the company. So unlike us LTS holders who over the years have tried to average down buy buying more he has just sold his allocation. This would help explain why he is not very interested in what happens to the share price.
Hi Leem1 you did well to get out when you did, I think I may have an idea why the price is still falling, Schroder sold 3.22mill shares in September 2021 , taking their share of the company down from 9.27% to 3.61% (I do not recall a RSM from the company on this though) ,It would take many weeks for the brokers to dispose of the stock given the low level of dealing. It is now December and hopefully they have found a home for the 3.11 million shares.
At the 10 Dec 2021, this is the state of the Major Share holders Obotritia 10.72%, Griffiths Richard 7.97%, Octopus 5.87% Rosetta 5.64% ,Arix capt5.26%, Schoder 3.61%, The Invus Group 3.04%, Evans Sir Christopher 2.95%, Evans Mark 1.56%, Spreadex 1.17%, The only purchases from the above from September 2021 are from Invus group why bought 1.73 mill shares and Aberdeen Asset who bought 0.59 mill shares. None of the Major share holders have sold except Schroder.
With over 3.22 million share being offloaded the there will always be a downward pressure on the SP.
As a LTSH I hope next year will bring a rise in the SP and no more large sales from the big players.
Nickolas Peter I to have eternal hope but even after Zacks increased the rating on Reneuron from hold to buy on the 7th Dec the price is still going down, And I am not sure how much more it will go. I think Leem1 had lost patience and got out but as a long term holder I will give a few more months.
As a background to the Q & A session I would like to log the major shareholders,
GP Jersey ltd 8.6%, Fitzpatrick Jon 3.45% Fitzpatrick Alaster Muir 3.21% Spreadex Ltd 1.55% Maccallum James Gibson0.88% Reynolds Thomas 0.32%
I think the above will have a big say on any deal being done
You are right PC, The American Banking News today 19 th Nov have listed ReNeuron as having crossed below the 200 day moving average on Thursday the 18th Nov. They comment that the 200 day moving average was £110.6 and ReNeuron traded as low as £99 and closed at £104 with a volume of 259,022 shares,
This may explain the lack of any US buying today but they may start buying when their market opens later.
All us long time share holders are well below water level with regard the share price. Most of the large long term holders have sold out at a loss they include Woodford, Wales life, Invesco, Aviva & Majedie. They have been replaced by Obotritia, Richard Griffiths, Octopus, Rosetta & Arix which together own over 35% of the company. Most of these major share holders have paid around 75p a share and unlike the long term holders, they are still showing a good profit on there investment. I am a bit concerned on the gradual decline in the share price as the last time the share price fell below £1 it was followed by a cash raise and share issue by the company. I was encouraged buy the purchase by Barbara Stachelin out new Finance Director of 43000shares at 1.15 p last month and it led me to buy more at the same price to bring my average price down but the price has slipped since then. I also note that Stifel Nicolaus & co, Analyst Glennie Christian has ReNeuron as a strong buy with a target price of 400p.as at 3rd Nov 2012. I hope all us Patient long term holders will see our patience rewarded soon.